TGR5

Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 3, 2023
Rat, Chronic kidney disease, Abdominal distension, Diarrhea, Classification, Dehydration, Food, IBS-C, NDA, Constipation, Prescription, TGR5, Medicine, Metis, Sale, Dialysis, Death, Incidence, Jefferies Group, Patient, Investment, NKF, Physician, Machine learning, Risk, Drug discovery, National Kidney Foundation, Growth, AI, Research, FDA, Letter, Therapy, CKD, Regulation of tobacco by the U.S. Food and Drug Administration, Human, Safety, D, Mobile phone, Pharmaceutical industry, Birth control

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • “During the first quarter of 2023, we demonstrated progress towards achieving our goals for 2023.
  • Ardelyx presented three posters covering additional positive clinical observations of XPHOZAH at the National Kidney Foundation (NKF) 2023 Spring Clinical Meetings, which took place in Austin, TX from April 11-15, 2023.
  • R&D Expenses: Research and development expenses were $9.1 million for the quarter ended March 31, 2023, compared to $8.9 million for the quarter ended March 31, 2022.
  • SG&A Expenses: Selling, general and administrative expenses were $26.8 million for the quarter ended March 31, 2023, an increase of $7.5 million compared to $19.3 million for the quarter ended March 31, 2022.

Metabolon Launches Bile Acids and Short Chain Fatty Acids Targeted Panels to Advance Understanding of Microbiome and Gut Metabolome in Health and Disease

Retrieved on: 
Tuesday, April 4, 2023
FXR, Diet, Diabetes, Cholesterol, Lipid, Metabolomics, Physiology, Fermentation, TGR5, Research, Biomarker, Microbiota, Colon, Inflammatory bowel disease, Short, SFCA Lignel 46 Coach, Content discovery platform, Risk, Cancer, Medicine, SCFA, Biology, Liver, Extrapyramidal system, Health, Phenotype, Neurology, Disease, Medical imaging, Dietary supplement, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., April 4, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch of its Bile Acids and Short Chain Fatty Acids Targeted Panels that measure microbially-derived metabolites of biological significance to identify biomarkers for the prediction and early detection of disease areas, including oncology, neurology, liver, diabetes, and gastrointestinal, and gut health.

Key Points: 
  • Short Chain Fatty Acids (SCFAs) are produced in the colon by the gut microbiota and are the end products of the anaerobic fermentation of dietary fibers and protein/peptides in the small intestine.
  • Metabolon's Bile Acids Targeted Panel measures 21 metabolites and has been designed specifically to advance pre-clinical research identifying bile-acid related biomarkers in digestive, metabolic, and neurological health.
  • "Metabolon is committed to advancing scientific understanding of the human microbiome and its impact on human health.
  • Our Bile Acids and Short Chain Fatty Acids Targeted Panels address an important need for today's cutting-edge researchers and will help unlock new insights into the complex interplay between diet, gut health, and disease, paving the way for the development of more personalized, targeted therapies."